Dexcom CGM
line of continuous glucose monitors
The Dexcom CGM is a continuous glucose monitoring system developed by Dexcom, Inc., a company specializing in glucose monitoring technology for individuals with diabetes. Several iterations of the Dexcom CGM wearable device have been released, beginning with the Dexcom Short-Term Sensor (STS), followed by the Dexcom Seven and Dexcom Seven Plus. Later models include the Dexcom G4, Dexcom G5, Dexcom G6, and Dexcom G7. The most recently released model, Stelo by Dexcom, is a more affordable option designed for individuals with type 2 diabetes.
Dexcom was founded in 1999 by John Burd and released its first CGM, the Dexcom STS, in 2006 following U.S. Food and Drug Administration (FDA) approval. As of 2025, only the Dexcom G6, Dexcom G7, and Stelo remain available.
Devices
Early Dexcom CGMs
The Dexcom Short-Term Sensor, commonly abbreviated as STS, was a three-day continuous glucose monitor designed to provide real-time glucose readings to assist individuals with type 1 (insulin-dependent) diabetes in managing their blood sugar levels. The STS received approval from the FDA in March 2006.
The STS was considered valuable for trend information, but not sufficiently accurate for insulin dosage decisions. The original STS was discontinued in 2007 and 2008 following the release of an improved device, the Dexcom Seven.
“Dexcom CGM” enters the record as line of continuous glucose monitors. Crown Archives preserves that source wording while asking what Dexcom, line and continuous can confirm, complicate or overturn.
Why this record matters
“Dexcom CGM” is worth following because a concise public description often conceals a longer documentary argument. Here, Dexcom, line and continuous provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Sep 20, 2026. The linked authority identifier is Q136359511. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1999, 2006, 2025 and 2007.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Dexcom CGM”, its source revision and the description used here.
- Expand the search: follow Dexcom CGM primary sources, Dexcom CGM archive and Dexcom research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Dexcom CGM”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Dexcom CGM” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.